Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma.

Van Tine BA, Agulnik M, Olson RD, Walsh GM, Klausner A, Frank NE, Talley TT, Milhem MM.

Cancer Med. 2019 Jun;8(6):2994-3003. doi: 10.1002/cam4.2136. Epub 2019 Apr 23.

2.

Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.

Walsh GM.

Expert Rev Respir Med. 2018 Nov;12(11):957-963. doi: 10.1080/17476348.2018.1520095. Epub 2018 Sep 17. Review.

PMID:
30193532
3.

Reslizumab in the treatment of severe eosinophilic asthma: an update.

Walsh GM.

Immunotherapy. 2018 Jun;10(8):695-698. doi: 10.2217/imt-2017-0176. Epub 2018 Mar 20. Review.

PMID:
29554826
4.

Pro-inflammatory mediator responses from neonatal airway epithelial cells and early childhood wheeze.

Turner S, Miller D, Walsh GM, Scaife A, Power UF, Shields MD, Devereux G.

Pediatr Pulmonol. 2018 Jan;53(1):10-16. doi: 10.1002/ppul.23915. Epub 2017 Nov 14.

PMID:
29136347
5.

Biologics for asthma and allergy.

Walsh GM.

Curr Opin Otolaryngol Head Neck Surg. 2017 Jun;25(3):231-234. doi: 10.1097/MOO.0000000000000352. Review.

PMID:
28234780
6.

Effective antigen presentation to helper T cells by human eosinophils.

Farhan RK, Vickers MA, Ghaemmaghami AM, Hall AM, Barker RN, Walsh GM.

Immunology. 2016 Dec;149(4):413-422. doi: 10.1111/imm.12658. Epub 2016 Sep 20.

7.
8.

Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma - an update.

Walsh GM.

Expert Rev Clin Immunol. 2017 Feb;13(2):143-149. doi: 10.1080/1744666X.2016.1216316. Epub 2016 Aug 2. Review.

PMID:
27459348
9.

Severe eosinophilic asthma and mepolizumab.

Walsh GM.

Lancet Respir Med. 2016 Jul;4(7):528-529. doi: 10.1016/S2213-2600(16)30103-5. Epub 2016 May 10. No abstract available.

PMID:
27177492
10.

Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium.

Walsh GM, Shih AW, Solh Z, Golder M, Schubert P, Fearon M, Sheffield WP.

Transfus Med Rev. 2016 Apr;30(2):53-68. doi: 10.1016/j.tmrv.2016.02.003. Epub 2016 Feb 23.

PMID:
26962008
11.

Autophagy and Asthma.

Farooq MB, Walsh GM.

Clin Exp Allergy. 2016 Jan;46(1):7-9. doi: 10.1111/cea.12633. No abstract available.

PMID:
26767491
12.

Mepolizumab-based therapy in asthma: an update.

Walsh GM.

Curr Opin Allergy Clin Immunol. 2015 Aug;15(4):392-6. doi: 10.1097/ACI.0000000000000183. Review.

PMID:
26110690
13.

Anti-IL-4/-13 based therapy in asthma.

Walsh GM.

Expert Opin Emerg Drugs. 2015 Sep;20(3):349-52. doi: 10.1517/14728214.2015.1050377. Epub 2015 Jun 1. Review.

PMID:
26021492
14.

Airway epithelial cytokine responses in childhood wheeze are independent of atopic status.

McDougall CM, Helms PJ, Walsh GM.

Respir Med. 2015 Jun;109(6):689-700. doi: 10.1016/j.rmed.2015.04.001. Epub 2015 Apr 14.

15.

Plasma and Plasma Protein Product Transfusion: A Canadian Blood Services Centre for Innovation Symposium.

Zeller MP, Al-Habsi KS, Golder M, Walsh GM, Sheffield WP.

Transfus Med Rev. 2015 Jul;29(3):181-94. doi: 10.1016/j.tmrv.2015.03.003. Epub 2015 Mar 26.

PMID:
25862281
16.

Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors.

Holstein SA, Bigelow JC, Olson RD, Vestal RE, Walsh GM, Hohl RJ.

Invest New Drugs. 2015 Jun;33(3):594-602. doi: 10.1007/s10637-015-0220-z. Epub 2015 Feb 21.

PMID:
25698442
17.

Maternal vitamin D and E intakes during early pregnancy are associated with airway epithelial cell responses in neonates.

Miller DR, Turner SW, Spiteri-Cornish D, Scaife AR, Danielian PJ, Devereux GS, Walsh GM.

Clin Exp Allergy. 2015 May;45(5):920-927. doi: 10.1111/cea.12490.

PMID:
25616026
18.

Global proteome analysis identifies active immunoproteasome subunits in human platelets.

Klockenbusch C, Walsh GM, Brown LM, Hoffman MD, Ignatchenko V, Kislinger T, Kast J.

Mol Cell Proteomics. 2014 Dec;13(12):3308-19. doi: 10.1074/mcp.M113.031757. Epub 2014 Aug 21.

19.

Eosinophil overview: structure, biological properties, and key functions.

Lacy P, Rosenberg HF, Walsh GM.

Methods Mol Biol. 2014;1178:1-12. doi: 10.1007/978-1-4939-1016-8_1. Review.

PMID:
24986602
20.

Culture of airway epithelial cells from neonates sampled within 48-hours of birth.

Miller D, Turner SW, Spiteri-Cornish D, McInnes N, Scaife A, Danielian PJ, Devereux G, Walsh GM.

PLoS One. 2013 Nov 4;8(11):e78321. doi: 10.1371/journal.pone.0078321. eCollection 2013.

21.

An update on biologic-based therapy in asthma.

Walsh GM.

Immunotherapy. 2013 Nov;5(11):1255-64. doi: 10.2217/imt.13.118. Review.

PMID:
24188679
22.

Inhibitory effects of Montelukast on mediator release by nasal epithelial cells from asthmatic subjects with or without allergic rhinitis.

Scaife A, Miller D, Spiteri-Cornish D, Turner SW, Devereux GS, Walsh GM.

Respir Med. 2013 Dec;107(12):1859-65. doi: 10.1016/j.rmed.2013.09.006. Epub 2013 Sep 18.

23.

Therapeutic potential of targeting interleukin 5 in asthma.

Walsh GM.

BioDrugs. 2013 Dec;27(6):559-63. doi: 10.1007/s40259-013-0047-0. Review.

PMID:
23728885
24.
25.

Eosinophil apoptosis and clearance in asthma.

Walsh GM.

J Cell Death. 2013 Apr 17;6:17-25. doi: 10.4137/JCD.S10818. eCollection 2013. Review.

26.

Antagonism of cytokine-induced eosinophil accumulation in asthma.

Walsh GM.

Front Pharmacol. 2012 Nov 22;3:197. doi: 10.3389/fphar.2012.00197. eCollection 2012. No abstract available.

27.

Nasal and bronchial airway epithelial cell mediator release in children.

Pringle EJ, Richardson HB, Miller D, Cornish DS, Devereux GS, Walsh GM, Turner SW.

Pediatr Pulmonol. 2012 Dec;47(12):1215-25. doi: 10.1002/ppul.22672. Epub 2012 Sep 28.

PMID:
23024038
28.

Treatment options for postmenopausal osteoporosis.

Walsh GM.

Ther Clin Risk Manag. 2012;8:367-8. doi: 10.2147/TCRM.S36280. Epub 2012 Aug 28. No abstract available.

29.

An update on emerging drugs for asthma.

Walsh GM.

Expert Opin Emerg Drugs. 2012 Mar;17(1):37-42. doi: 10.1517/14728214.2012.657625. Epub 2012 Jan 31. Review.

PMID:
22292562
30.

Novel cytokine-directed therapies for asthma.

Walsh GM.

Discov Med. 2011 Apr;11(59):283-91. Review.

31.

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Walsh GM.

Curr Opin Investig Drugs. 2010 Nov;11(11):1305-12.

PMID:
21157650
32.

Integrin α(IIb)β₃ exists in an activated state in subjects with elevated plasma homocysteine levels.

McGarrigle SA, O'Neill S, Walsh GM, Moran N, Graham IM, Cooney MT, Monavari A, Mayne P, Collins P.

Platelets. 2011;22(1):65-73. doi: 10.3109/09537104.2010.512646. Epub 2010 Dec 6.

PMID:
21133649
33.

Mass spectrometry-based proteomics in biomedical research: emerging technologies and future strategies.

Walsh GM, Rogalski JC, Klockenbusch C, Kast J.

Expert Rev Mol Med. 2010 Sep 23;12:e30. doi: 10.1017/S1462399410001614. Review.

PMID:
20860882
34.

Targeting eosinophils in asthma: current and future state of cytokine- and chemokine-directed monoclonal therapy.

Walsh GM.

Expert Rev Clin Immunol. 2010 Sep;6(5):701-4. doi: 10.1586/eci.10.58. No abstract available.

PMID:
20828276
35.

Antagonism of eosinophil accumulation in asthma.

Walsh GM.

Recent Pat Inflamm Allergy Drug Discov. 2010 Nov;4(3):210-3. Review.

PMID:
20804449
36.

Reslizumab for pediatric eosinophilic esophagitis.

Walsh GM.

Immunotherapy. 2010 Jul;2(4):461-5. doi: 10.2217/imt.10.41.

PMID:
20636000
37.

Canakinumab for the treatment of cryopyrin-associated periodic syndromes.

Walsh GM.

Drugs Today (Barc). 2009 Oct;45(10):731-5. doi: 1396674/dot.2009.45.10.1416583. Review.

PMID:
20069137
38.

The anti-inflammatory effects of levocetirizine--are they clinically relevant or just an interesting additional effect?

Walsh GM.

Allergy Asthma Clin Immunol. 2009 Dec 17;5(1):14. doi: 10.1186/1710-1492-5-14.

39.

Mepolizumab and eosinophil-mediated disease.

Walsh GM.

Curr Med Chem. 2009;16(36):4774-8. Review.

PMID:
19929788
40.

Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions.

Robinson AJ, Kashanin D, O'Dowd F, Fitzgerald K, Williams V, Walsh GM.

Clin Exp Allergy. 2009 Dec;39(12):1866-74. doi: 10.1111/j.1365-2222.2009.03334.x. Epub 2009 Aug 18.

PMID:
19689459
41.

A signaling pathway contributing to platelet storage lesion development: targeting PI3-kinase-dependent Rap1 activation slows storage-induced platelet deterioration.

Schubert P, Thon JN, Walsh GM, Chen CH, Moore ED, Devine DV, Kast J.

Transfusion. 2009 Sep;49(9):1944-55. doi: 10.1111/j.1537-2995.2009.02224.x. Epub 2009 May 18.

42.
43.

Implementation of a data repository-driven approach for targeted proteomics experiments by multiple reaction monitoring.

Walsh GM, Lin S, Evans DM, Khosrovi-Eghbal A, Beavis RC, Kast J.

J Proteomics. 2009 Jul 21;72(5):838-52. doi: 10.1016/j.jprot.2008.11.015. Epub 2008 Dec 6.

44.

Identification of nitroxyl-induced modifications in human platelet proteins using a novel mass spectrometric detection method.

Hoffman MD, Walsh GM, Rogalski JC, Kast J.

Mol Cell Proteomics. 2009 May;8(5):887-903. doi: 10.1074/mcp.M800230-MCP200. Epub 2008 Dec 31.

45.

Emerging drugs for asthma.

Walsh GM.

Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. doi: 10.1517/14728210802591378 . Review. Erratum in: Expert Opin Emerg Drugs. 2009 Mar;14(1):205.

PMID:
19046132
46.

Sputum eosinophil apoptotic rate is positively correlated to exhaled nitric oxide in children.

Pontin J, Blaylock MG, Walsh GM, Turner SW.

Pediatr Pulmonol. 2008 Nov;43(11):1130-1134. doi: 10.1002/ppul.20921.

PMID:
18972415
47.

[Not Available].

Walsh GM.

Ther Clin Risk Manag. 2008 Jun;4(3):i-ii. No abstract available.

48.

[Not Available].

Walsh GM.

Ther Clin Risk Manag. 2008 Feb;4(1):i-ii. No abstract available.

49.

[Not Available].

Walsh GM.

Ther Clin Risk Manag. 2007 Dec;3(6):973-4. No abstract available.

50.

Statins as emerging treatments for asthma and chronic obstructive pulmonary disease.

Walsh GM.

Expert Rev Respir Med. 2008 Jun;2(3):329-35. doi: 10.1586/17476348.2.3.329.

PMID:
20477197

Supplemental Content

Loading ...
Support Center